Sonja Zweegman

39PUBLICATIONS
214CO-AUTHORS
Haematological tumoursNgā rongoā me ngā whakamaimoa o te Māori (Māori medicine and treatments)NanomedicineMedical bacteriologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (39)

|Sep 25, 2026
Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Transplant-Ineligible Subgroup Analysis of CEPHEUS.

|Sep 01, 2026
Spatial profiling identifies a distinct and topographically-defined tumor microenvironment that emerges during multiple myeloma evolution.

|Aug 24, 2026
Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis.

|Jun 03, 2026
Daratumumab in transplant-ineligible or -deferred newly diagnosed multiple myeloma: minimal residual disease in CEPHEUS.

|May 05, 2026
Infections in patients receiving daratumumab for newly diagnosed multiple myeloma: a pooled analysis of MAIA and ALCYONE.

|Mar 27, 2026
FDG-PET medullary total tumor volume highlights high-risk patients with newly diagnosed multiple myeloma in CASSIOPEIA trial.

Bastien Jamet, Shamimeh Ahrari, Sonja Zweegman

Pageof 7

Frequent Collaborators

11 joint publications

Pieter Sonneveld

9 joint publications

Niels W C J van de Donk

8 joint publications

Aurore Perrot

6 joint publications

Mark-David Levin